| Kelly Jean Summerfield, CNM | |
|
6221 N Telegraph Rd, Dearborn Heights, MI 48127-3222 | |
| (313) 561-2200 | |
| (313) 561-2211 |
| Full Name | Kelly Jean Summerfield |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 6221 N Telegraph Rd, Dearborn Heights, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871825703 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 4704213133 (Michigan) | Primary |
| Entity Name | Prime Garden City Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598179954 PECOS PAC ID: 6901702133 Enrollment ID: O20031209000857 |
News Archive
MAXIMUS, a leading provider of government services worldwide, announced the launch of a new podcast series that focuses on government health and human services programs.
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.
Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.
Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.
› Verified 2 days ago
| Entity Name | Haddad Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679928717 PECOS PAC ID: 8022351766 Enrollment ID: O20190520002344 |
News Archive
MAXIMUS, a leading provider of government services worldwide, announced the launch of a new podcast series that focuses on government health and human services programs.
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.
Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.
Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Jean Summerfield, CNM 6221 N Telegraph Rd, Dearborn Heights, MI 48127-3222 Ph: (313) 561-2200 | Kelly Jean Summerfield, CNM 6221 N Telegraph Rd, Dearborn Heights, MI 48127-3222 Ph: (313) 561-2200 |
News Archive
MAXIMUS, a leading provider of government services worldwide, announced the launch of a new podcast series that focuses on government health and human services programs.
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.
Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.
Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.
› Verified 2 days ago